CompanyDrug

Sanofi’s Efdoralprin Alfa Demonstrates Superior fAAT Normalization in Alpha-1 Antitrypsin Deficiency Phase II ElevAATe Study

Others

Takeda Faces $885M Antitrust Verdict in Amitiza “Pay-for-Delay” Litigation; Damages to be Trebled Under U.S. Law

Novartis' Pluvicto Demonstrates Significant PSA Response Improvement in PSMA-Positive mHSPC Patients in PSMAddition Study
CompanyDrug

Novartis’ Pluvicto Demonstrates Significant PSA Response Improvement in PSMA-Positive mHSPC Patients in PSMAddition Study

Company

China Population Welfare Foundation and Lilly China Launch “Tuohu Chang’an” Patient Assistance Program for Inflammatory Bowel Disease

CompanyDeals

Hybio Pharmaceutical Partners with Undisclosed Chinese Firms for GLP-1 API Commercialization in Americas Markets

CompanyMedical Device

Shanghai ZJ Bio-Tech Secures International Approvals for Molecular Diagnostic Platforms in Netherlands and Mexico

CompanyDeals

Shandong Buchang Pharmaceuticals Secures Exclusive License for KYN003 Broad-Spectrum Influenza Vaccine Through Strategic Partnership with Hefei Keyinuo

CompanyDrug

Bayer’s Asundexian Receives FDA Priority Review for Secondary Stroke Prevention Following Positive Phase III OCEANIC-STROKE Trial

UCB's BIMZELX Demonstrates Superior Joint Outcomes vs SKYRIZI in Phase III BE BOLD Trial for Psoriatic Arthritis
Others

UCB’s BIMZELX Demonstrates Superior Joint Outcomes vs SKYRIZI in Phase III BE BOLD Trial for Psoriatic Arthritis

CompanyDrug

United Laboratories Secures NMPA Tacit Approval for TUL108 Clinical Study in China Following US Trial Authorization

CompanyDrug

ImmuneOnco Doses First Patient in Phase II Trial of IMM0306 for Systemic Lupus Erythematosus

CompanyDrug

Bio-Thera Solutions Secures FDA Approval for Golimumab Biosimilars Immgolis and Immgolis Intri